December 16, 2018, Coralville, IA. – Emmyon is pleased to announce that Dr. John Talley has become the company’s Vice President of Chemistry. John has served as senior scientific advisor at Emmyon and led the company’s chemistry program since 2012.  He is one of the world’s most accomplished medicinal chemists and an inventor on more than 200 issued U.S. patents.  His inventions include the COX-2 specific inhibitors Celebrex®, Bextra®, Dynastat®, Deramaxx® and Trocoxil® and the hydroxyethyl sulfonamide class of inhibitors for the treatment of HIV/AIDS, marketed under the brand names of Agenerase® , Telzir® , and Prezista®.  The medicines invented by Dr. Talley have improved the health of millions of patients and generated over $40 billion in sales to date.  He received the prestigious PhRMA Discoverers Award in 2002 for the discovery of Celebrex®. For the past four years (2015-2018), Dr. Talley has been named to The Medicine Maker Power List, which recognizes the world’s most influential people in drug discovery and development.

November 27, 2018, Coralville, IA. – Emmyon is pleased to announce that the United States Patent and Trademark Office has today issued a new patent for the use of ursolic acid to enhance muscle formation, increase muscle mass, or reduce muscle atrophy. This new patent, which has been exclusively licensed to Emmyon from the University of Iowa Research Foundation, complements and greatly strengthens Emmyon’s IP coverage of ursolic acid in the United States. The patent’s lead inventor is Emmyon’s President, Chris Adams, MD, PhD.

September 30, 2018, Coralville, IA – Emmyon is pleased to announce that it has received a new Phase II Small Business Innovation Research (SBIR) award from the National Institute on Aging (NIA) at the US National Institutes of Health (NIH).  The funding will support further development of novel pharmaceutical compounds for skeletal muscle atrophy.

Skeletal muscle atrophy, also known as muscle wasting, is a widespread and serious condition that affects tens of millions of people in the US alone.  Causes of muscle atrophy include aging, malnutrition, muscle disuse, critical illness, certain medications, and a broad range of chronic illnesses including cancer, heart failure, COPD, diabetes, renal failure, cirrhosis, rheumatoid arthritis, and HIV/AIDS.  Effects of muscle atrophy include weakness, impaired activity, falls, prolonged hospitalization, delayed rehabilitation, loss of independent living, and increased mortality.  Unfortunately, right now, we do not have any medicines to help prevent or treat muscle atrophy.  Our research seeks to address this problem.  We’re very grateful to the NIA and the NIH for their continued support of these efforts.

April 20, 2017, Coralville, IA. – We are pleased to announce that the National Institutes of Health (NIH) has selected Emmyon to exhibit and showcase its technology at the 2017 BIO International Convention, which will be held in San Diego, CA from June 19-22, 2017.  Emmyon will be located within the NIH’s Innovation Zone.  We’re honored and excited to participate as an NIH-sponsored company at the world’s largest biotechnology conference and exhibition.

September 1, 2016, Coralville, IA. – Emmyon is delighted to announce that its Senior Scientific Advisor, Dr. John Talley, has been named, for the second year in a row, to the highly prestigious Power List of The Medicine Maker magazine.  In the 2016 Power List, Dr. Talley was named as the world’s 17th most influential person in drug discovery and development.

April 1, 2016, Coralville, IA – Emmyon is pleased to announce that it has received a new Phase I SBIR award from the National Institutes of Health.  The funding will support development of pharmaceuticals for skeletal muscle atrophy and weakness.